Evidence map›Paper›PMID 30293230›Full record

Trial reportClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.

N Martínez, M Herrera, L Frías, M Provencio, R Pérez-Carrión, V Díaz, Michael Morse, M C Crespo

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 4 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 2 countries.

N MartínezHospital Universitario Ramón y Cajal, Madrid, Spain.
M HerreraHospital Clínico San Carlos, Madrid, Spain.
L FríasHospital Universitario La Paz, Madrid, Spain.
M ProvencioHospital Universitario Puerta de Hierro, Madrid, Spain.
R Pérez-CarriónHospital Universitario Quirón, Madrid, Spain.
V DíazHospital Universitario Puerta del Mar, Cádiz, Spain.
Michael MorseOliventures, Raleigh, NC, USA. Michaelaaronmorse@hotmail.com.ORCID http://orcid.org/0000-0002-5725-4533
M C CrespoIMDEA-Food, CEI UAM + CSIC, Madrid, Spain.
Hospital Clínico San Carlos · ESHospital Universitario La Paz · ESHospital Universitario Puerta de Hierro Majadahonda · ESHospital Universitario Puerta del Mar · ESHospital Universitario Quirónsalud Madrid · ESHospital Universitario Ramón y Cajal · ESMadrid Institute for Advanced Studies · ESNorth Carolina State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBreast cancer patients receiving hormonal therapies face risks of relapse, increased rates of cardiovascular events, and toxicities of therapy such as aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS). C-reactive protein (CRP), a marker for inflammation, is associated with breast cancer outcomes. We evaluated whether the olive-derived polyphenol hydroxytyrosol combined with omega-3 fatty acids and curcumin would reduce CRP and musculoskeletal symptoms in breast cancer patients receiving adjuvant hormonal therapies. EXPERIMENTAL

designThis prospective, multicenter, open-label, single arm, clinical trial enrolled post-menopausal breast cancer patients (n = 45) with elevated C-reactive protein (CRP) taking predominantly aromatase inhibitors to receive a combination of hydroxytyrosol, omega-3 fatty acids, and curcumin for 1 month. CRP, other inflammation-associated cytokines, and pain scores on the Brief Pain Inventory were measured before therapy, at the end of therapy and 1 month after completion of therapy.

resultsCRP levels declined during the therapy [from 8.2 ± 6.4 mg/L at baseline to 5.3 ± 3.2 mg/L (p = 0.014) at 30 days of treatment], and remained decreased during the additional 1 month off therapy. Subjects with the highest baseline CRP levels had the greatest decrease with the therapy. Pain scores also decreased during the therapy. There were no significant adverse events.

conclusionsThe combination of hydroxytyrosol, omega-3 fatty acids, and curcumin reduced inflammation as indicated by a reduction in CRP and reduced pain in patients with aromatase-induced musculoskeletal symptoms. Longer studies comparing this combination to other anti-inflammatories in larger groups of patients with clinical outcome endpoints are warranted.

Indexed as

AdultAgedAged, 80 and overAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantC-Reactive ProteinCurcuminDrug CombinationsFatty Acids, Omega-3FemaleHumansInflammationMiddle AgedMusculoskeletal PainPhenylethyl Alcohol3,4-dihydroxyphenylethanolAromatase InhibitorsC-Reactive ProteinCurcuminDrug CombinationsFatty Acids, Omega-3Phenylethyl AlcoholAI-musculoskeletal syndromeBrief pain indexCRP

Identifiers

PMID30293230
OpenAlexW2895633239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.